S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
BREAKING: Tiny biotech successfully treats blindness (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NYSE:ENFN

Enfusion (ENFN) Stock Forecast, Price & News

$7.88
+0.08 (+1.03%)
(As of 05/26/2023 ET)
Compare
Today's Range
$7.79
$8.03
50-Day Range
$7.54
$10.50
52-Week Range
$7.37
$16.76
Volume
571,676 shs
Average Volume
404,192 shs
Market Capitalization
$916.37 million
P/E Ratio
197.05
Dividend Yield
N/A
Price Target
$11.08

Enfusion MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
40.7% Upside
$11.08 Price Target
Short Interest
Healthy
4.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of Enfusion in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$11.56 M Sold Last Quarter
Proj. Earnings Growth
66.67%
From $0.12 to $0.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Computer And Technology Sector

108th out of 623 stocks

Prepackaged Software Industry

28th out of 217 stocks


ENFN stock logo

About Enfusion (NYSE:ENFN) Stock

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

ENFN Stock News Headlines

Enfusion (NYSE:ENFN) Stock Price Up 2.7%
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Piper Sandler Reaffirms Their Hold Rating on Enfusion (ENFN)
Bull Of The Day: Enfusion (ENFN)
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
Enfusion, Inc. (ENFN) Q1 Earnings Meet Estimates
Enfusion (ENFN) to Release Quarterly Earnings on Tuesday
Enfusion Announces Date of First Quarter 2023 Results
Enfusion (NYSE:ENFN) Sees Strong Trading Volume
Enfusion: Still Very Attractive
What 4 Analyst Ratings Have To Say About Enfusion
See More Headlines
Receive ENFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter.

ENFN Company Calendar

Last Earnings
3/07/2023
Today
5/27/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Fax
N/A
Employees
1,006
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.08
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+40.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-7,650,000.00
Pretax Margin
3.36%

Debt

Sales & Book Value

Annual Sales
$150.35 million
Book Value
$0.85 per share

Miscellaneous

Free Float
69,655,000
Market Cap
$916.37 million
Optionable
Not Optionable
Beta
0.43

Key Executives

  • Mr. Oleg Movchan (Age 49)
    CEO & Director
  • Mr. Stephen Malherbe
    Managing Partner
  • Mr. Bradley Herring (Age 52)
    Chief Financial Officer
  • Mr. Michael Berry
    Chief Operating Officer
  • Mr. Daniel Groman (Age 34)
    Chief Technology Officer
  • Mr. Brian Murphy
    Investor
  • Ms. Lorelei M. Skillman (Age 53)
    Chief Marketing & Communications Officer
  • Ms. Bronwen Bastone (Age 50)
    Chief People Officer
  • Mr. Kabir Kohli
    MD of Managed Services Solutioning & Global Head of Client Services
  • Mr. Joseph Defeo
    Global Head of Managed Services Production













ENFN Stock - Frequently Asked Questions

Should I buy or sell Enfusion stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares.
View ENFN analyst ratings
or view top-rated stocks.

What is Enfusion's stock price forecast for 2023?

5 brokers have issued 1 year target prices for Enfusion's stock. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's share price to reach $11.08 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price.
View analysts price targets for ENFN
or view top-rated stocks among Wall Street analysts.

How have ENFN shares performed in 2023?

Enfusion's stock was trading at $9.67 on January 1st, 2023. Since then, ENFN shares have decreased by 18.5% and is now trading at $7.88.
View the best growth stocks for 2023 here
.

When is Enfusion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ENFN earnings forecast
.

How were Enfusion's earnings last quarter?

Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Tuesday, March, 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $40.52 million for the quarter, compared to analysts' expectations of $39.88 million. Enfusion had a net margin of 1.81% and a trailing twelve-month return on equity of 2.81%.

What ETF holds Enfusion's stock ?

Direxion Daily Cloud Computing Bull 2x holds 378 shares of ENFN stock, representing 0.05% of its portfolio.

What guidance has Enfusion issued on next quarter's earnings?

Enfusion issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$190.00 million, compared to the consensus revenue estimate of $188.13 million.

When did Enfusion IPO?

(ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share.

What is Enfusion's stock symbol?

Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN."

Who are Enfusion's major shareholders?

Enfusion's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (7.26%), BlackRock Inc. (1.35%), New York State Common Retirement Fund (1.05%), New York State Common Retirement Fund (1.05%), Wasatch Advisors LP (0.48%) and State Street Corp (0.45%). Insiders that own company stock include Dan Groman, Hillhouse Investment Managemen, Roy Luo, Stephen Malherbe and Tarek Hammoud.
View institutional ownership trends
.

How do I buy shares of Enfusion?

Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enfusion's stock price today?

One share of ENFN stock can currently be purchased for approximately $7.88.

How much money does Enfusion make?

Enfusion (NYSE:ENFN) has a market capitalization of $916.37 million and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How many employees does Enfusion have?

The company employs 1,006 workers across the globe.

How can I contact Enfusion?

The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com.

This page (NYSE:ENFN) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -